March 2008 Mentor of the Month: Loralie Langman
Loralie Langman, PhD

Loralie Langman, PhD got her BSc in Laboratory Medicine and Pathology, CSMLS, and ASCP certifications at the University of Alberta and University of Alberta Hospital.  After working for a few years as a laboratory technologist, she then went back to school and completed her Ph.D. in Medicine – Laboratory Medicine and Pathology at the University of Alberta.  She completed her Clinical Chemistry training at the University of Toronto, specializing in Forensic Toxicology and Molecular Genetics.  Prior to coming to Mayo Clinic Rochester, she was in Vancouver, British Columbia, at the Provincial Toxicology Centre and BC Biomedical Laboratories as a Forensic Toxicologist/Clinical Chemist. 

Dr. Langman was certified with the Canadian Academy of Clinical Biochemistry (CACB) and is the first individual to have achieved Diplomat status with the American Board of Clinical Chemistry (ABCC) in all three disciplines (Clinical Chemistry, Molecular Diagnostics, and Toxicological Chemistry).  She is also a Diplomat with the American Board of Forensic Toxicologists.

Dr. Langman is a member of and serves on committees for several professional organizations including: The Society of Forensic Toxicologists; the American Academy of Forensic Sciences; the National Academy of Clinical Biochemistry; the American Association for Clinical Chemistry; the Canadian Society of Clinical Chemists; the International Association of Therapeutic Drug Monitoring and Clinical Toxicology; and The International Association of Forensic Toxicologists.

Currently, Dr. Langman is Director of the Drug/Toxicology Laboratory at Mayo Clinic Rochester.  She has over 30 publications and over 40 abstracts/presentations at National and International meetings.  Her areas of expertise include: toxicology; drugs of abuse (particularly amphetamine-type stimulants and cocaine); post-mortem toxicology; therapeutic drug management; and pharmacogenetics.  Her current research interests include metabolism and pharmacogenomics of amphetamine-type stimulants and cocaine; and genotype phenotype relationships of psychoactive medications.

Page Access: